About this episode
In this edition, we have Dr. Teele Kuusk (UK), the associate editor of the UROONCO RCC educational platform discussing kidney cancer highlights at the recent ESMO2022.
Dr. Kuusk begins with the reporting of several new trials and the accompanying results, which include: Phase 3 CheckMate-914, Phase 3 COSMIC-313, Phase 2 Keynote-B61, and Cohort 1 of LITESPARK-003 study.
After delivering the trial results, Dr. Kuusk shares the possible reasons why the adjuvant trials failed.
For more details on the results of the LITESPARK-003 study, you can watch this video featuring Assoc. Prof. Jaime Merchan (US), who presented at ESMO2022. https://kidney.uroonco.uroweb.org/video/cohort-1-of-litespark-003/
This article was first posted on UROONCO.
Get every episode summarized
Each time EAU Podcasts publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from EAU Podcasts
EAUN edition - No place to go: Homelessness & Incontinence
EAU Podcasts
EAU Section of Genitourinary Reconstructive Surgeons: Management of short bulbar...
EAU Podcasts
History Office: Ongoing discoveries from the life of Joaquín Albarrán (1860-1912...
EAU Podcasts
PEACE 2 results: Evaluating pelvic RT for very high-risk PCa
EAU Podcasts